Panoramic Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Panoramic Capital’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,806	Closed	-$483K	–	48
2024 Q4	$483K	Buy	+45,806	New	+$642K	0.26%	41

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Panoramic Capital's SPRY Position: Q1 2025 in Review

Panoramic Capital sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 45,806 shares — an estimated $483K sold.

Panoramic Capital first reported a position in SPRY in Q4 2024 and held it in 1 quarter. The position peaked at $483K in Q4 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

Panoramic Capital reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Panoramic Capital sold 45,806 ARS Pharmaceuticals shares in Q1 2025, an estimated $483K.
Panoramic Capital first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Panoramic Capital's ARS Pharmaceuticals position peaked at $483K in Q4 2024.
184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Panoramic Capital's 13F filing for Q1 2025, filed 15 May 2025.